DK1181319T3 - Kimære DR4-antistoffer og anvendelser deraf - Google Patents

Kimære DR4-antistoffer og anvendelser deraf

Info

Publication number
DK1181319T3
DK1181319T3 DK00937844T DK00937844T DK1181319T3 DK 1181319 T3 DK1181319 T3 DK 1181319T3 DK 00937844 T DK00937844 T DK 00937844T DK 00937844 T DK00937844 T DK 00937844T DK 1181319 T3 DK1181319 T3 DK 1181319T3
Authority
DK
Denmark
Prior art keywords
antibodies
chimeric
kits
diagnosis
articles
Prior art date
Application number
DK00937844T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Anan Chuntharapai
Kelly H Dodge
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1181319T3 publication Critical patent/DK1181319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DK00937844T 1999-05-28 2000-05-25 Kimære DR4-antistoffer og anvendelser deraf DK1181319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
PCT/US2000/014599 WO2000073349A1 (en) 1999-05-28 2000-05-25 Dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK1181319T3 true DK1181319T3 (da) 2009-08-17

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00937844T DK1181319T3 (da) 1999-05-28 2000-05-25 Kimære DR4-antistoffer og anvendelser deraf

Country Status (12)

Country Link
EP (2) EP1181319B1 (da)
JP (1) JP4589586B2 (da)
AT (1) ATE429450T1 (da)
AU (3) AU781952B2 (da)
CA (1) CA2374599A1 (da)
CY (1) CY1109151T1 (da)
DE (1) DE60042066D1 (da)
DK (1) DK1181319T3 (da)
ES (1) ES2325305T3 (da)
IL (1) IL146448A0 (da)
PT (1) PT1181319E (da)
WO (1) WO2000073349A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
JP2002543151A (ja) * 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
JP4589586B2 (ja) * 1999-05-28 2010-12-01 ジェネンテック， インコーポレイテッド Ｄｒ４抗体とその利用
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1409544B1 (en) 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AU2005264993A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Use of Apo2L receptor agonists and NK cells or NK cell activators
CN102978277A (zh) 2004-08-06 2013-03-20 健泰科生物技术公司 使用生物标志的测定法和方法
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006210838B2 (en) 2005-02-02 2011-10-20 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
CA2619759A1 (en) * 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for galnac-t14 expression in cells/tissues
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
EP2793940B1 (en) * 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US6342363B1 (en) * 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
PT1860187E (pt) * 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
PT1086138E (pt) * 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
JP4589586B2 (ja) * 1999-05-28 2010-12-01 ジェネンテック， インコーポレイテッド Ｄｒ４抗体とその利用

Also Published As

Publication number Publication date
WO2000073349A9 (en) 2002-05-10
IL146448A0 (en) 2002-07-25
AU2005201915A1 (en) 2005-06-02
AU2005201915B2 (en) 2009-01-22
JP4589586B2 (ja) 2010-12-01
CA2374599A1 (en) 2000-12-07
EP1181319B1 (en) 2009-04-22
ATE429450T1 (de) 2009-05-15
PT1181319E (pt) 2009-07-14
WO2000073349A1 (en) 2000-12-07
AU781952B2 (en) 2005-06-23
EP2213302A2 (en) 2010-08-04
JP2003503017A (ja) 2003-01-28
AU5296700A (en) 2000-12-18
EP2213302A3 (en) 2010-11-03
EP1181319A1 (en) 2002-02-27
ES2325305T3 (es) 2009-09-01
DE60042066D1 (de) 2009-06-04
CY1109151T1 (el) 2014-07-02
AU2009201670A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO20061736L (no) Krystallform av epotilon B
IS6667A (is) Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
NZ513629A (en) C-21 modified epothilones
DK1200418T3 (da) Nematodicide trifluorbutener
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
SE9904377D0 (sv) Pharmaceutical combinations
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
ID25478A (id) Agonis 5-ht1f
DE69421665D1 (de) Anomere Fluorribosylamine
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao